We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Severe Plaque Psoriasis

News List

FDA Approves STELARA for Adolescents with Moderate to Severe Plaque Psoriasis americanpharmaceuticacreview
October 17, 2017
Today's approval marks a significant milestone for this age group as approximately one-third of individuals who develop plaque psoriasis do so before 20 years of age, and there are limited treatment options for adolescents.
Janssen Announces FDA Approval of TREMFYA for Severe Plaque Psoriasis americanpharmaceuticalreview
July 18, 2017
Janssen Biotech announced the U.S. Food and Drug Administration (FDA) has approved TREMFYA (guselkumab) for the treatment of adults living with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.